论文部分内容阅读
目的:研制连香方药的自微乳载药系统。方法:经溶解度试验初步筛选后,采用三元相图法研究不同表面活性剂、助表面活性剂和油相体系自微乳化的能力和组成区域,筛选表面活性剂和助表面活性剂;在此基础上,考察方药组分、介质、温度等因素对体系自微乳化的能力和组成区域的影响,结合微乳粒径测定,筛选连香方药自微乳处方;进行稳定性及自微乳化速率的考察,初步评价自微乳处方。结果:优化的处方为黄连总生物碱-丁香油-Cremophor RH60-1,2-丙二醇(40∶20∶60∶20,w/w);处方经分散后可得到平均粒径为17.4 nm、PDI为0.176的微乳,稳定性好,自微乳化效率高。结论:优化的处方可作为连香方药的自微乳载药系统供后续研究。
Objective: To develop a self-microemulsion drug delivery system with even prescription. Methods: After preliminary screening by the solubility test, the ternary phase diagrams were used to study the self-microemulsifying ability and compositional area of different surfactants, cosurfactants and oil phase systems, and to screen the surfactants and cosurfactants; On the basis of this, the effects of prescriptions, media and temperature on the self-microemulsifying ability and compositional area of the system were investigated. With the determination of the microemulsion particle size, the prescription of the self-microemulsion of Lianxiangfang was screened. The stability and self-microemulsification rate Study, a preliminary evaluation of self-microemulsion prescription. Results: The optimal prescription was Coptidis Rhizoma Coptidis RH60-1,2-propanediol (40:20:60:20, w / w). The average particle size after PDL dispersion was 17.4 nm. PDI 0.176 microemulsion, good stability, high self-microemulsification efficiency. CONCLUSIONS: The optimized prescription can be used as a self-microemulsion drug-carrying system for the study of the prescription of the prescription.